Transcatheter Mitral Valve Implantation Market Size Worth USD 9.15 Billion in 2032

Advertisement

Advancements in the techniques of Transcatheter Mitral Valve Implantation, substantial prevalence of Mitral Regurgitation with favorable reimbursement scenarios are expected to fuel the Transcatheter Mitral Valve Implantation Market growth

Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) — The global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 9.15 billion by 2032, at a CAGR of 14.4% according to recent analysis by Emergen Research. Rise frequency of mitral valve diseases, increasing pioneering pipeline devices together with rising elderly population with heart condition is positively driving the growth prospects of the Transcatheter Mitral Valve Implantation (repair and replacement) market in the forecast period. Mitral Regurgitation (MR) is the greatest widespread valve disorder affecting more than 4 million in total in the United States. Roughly, 250,000 cases of mitral regurgitation are recorded in the United States annually out of which close to 50,000 patients decide to undertake recommended surgery. Transcatheter mitral valve replacement (TMVR) is a substitute therapeutic opportunity which has been enhanced considerably to competently treat severe mitral regurgitation in patients who are exposed to high or prohibitive surgical risks.

A practicable and comparatively safe option in patients with mitral regurgitation is established called percutaneous transcatheter mitral valve replacement. In terms of safety and effectiveness this techniques is proving to be beneficial for those patients with potential risk of mitral value disease. The demand for this technique is enhancing the growth prospects of the global transcatheter mitral valve implantation over the forecast period. However, cases of failed surgeries, costly target surgeries, and rigorous government rules and regulations are likely to hinder the industry growth in forecast period.

Advertisement

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/54

PARAMETERS DETAILS
The market size value in 2019 USD 1.82 Billion
CAGR (2023 – 2032) 14.4%
The revenue forecast in 2032 USD 9.15 Billion
Base year for estimation 2022
Historical data 2019-2021
Forecast period 2023-2032
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Product, Application, End use, Region
Regional scope North America; Europe; Asia Pacific; Central & South America; MEA
Country scope U.S.; Canada; Mexico; U.K.; Germany; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Saudi Arabia; South Africa; Turkey
Key companies profiled Abbott Laboratories, HLT Medical, Neovasc, Edward Lifesciences, Biotronik Private Limited, LivaNova, Colibri Heart Valve, Medtronic, NeoChord, MValve Technologies, Transcatheter Technologies GmbH and Venus Medtech
Customization scope 10 hrs of free customization and expert consultation

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @

https://www.emergenresearch.com/request-discount/54

MAJOR COMPANIES and Market Share Analysis

  • Abbott Laboratories
  • HLT Medical
  • Neovasc
  • Edward Lifesciences
  • Biotronik Private Limited
  • LivaNova, Colibri Heart Valve
  • Medtronic
  • NeoChord
  • MValve Technologies
  • Transcatheter Technologies GmbH
  • Venus Medtech

Strategic Development

  • In January 2020, Abbott’s Tendyne Transcatheter Mitral Valve Implantation (TMVI) system is approved in Europe and has also received a CE Mark. This therapy is likely to treat mitral regurgitation (MR) in patients requiring a heart valve repair or replacement
  • In March 2019, MitraClip’s indications to address the secondary MR was expanded and approved by US Food and Drug Administration (FDA) to develop functional (secondary) mitral regurgitation. This can be administered in patients whose mitral valve is functioning normally, however structural changes in the heart (such as enlargement due to heart failure) are no longer allowing computation of the mitral leaflets.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @

https://www.emergenresearch.com/select-license/54

Further key findings from the report suggest

  • To develop functional (secondary) mitral regurgitation, in March 2019, MitraClip’s suggestions to address the secondary MR was expanded and approved by US Food and Drug Administration (FDA). This can be administered in patients with structural changes in the heart (such as enlargement due to heart failure)
  • As mechanical values last long up to approximately 25 years post implant/surgery, mechanical valves segment is anticipated to dominate the industry with a market share of almost, 58.3%
  • Mitral Valve Stenosis dominates the market in terms of market share of approximately 44.1% in 2019. However, Mitral Valve Regurgitation segment in the applications outlook registered highest growth rate of approximately 14.1% owing to rise in conditions of mitral regurgitation and due to expansion of potential techniques for successful surgeries
  • Minneapolis based CardioMech AS, a medical device company is developing a transfemoral, transseptally delivered mitral valve repair technology for which in August 2020, it raised fund worth USD 18.5 million for its first-in-human feasibility trial
  • North America dominated the market in terms of market revenue in 2019. Factors contributing to the largest market share (39.7%) are increasing success rate of surgeries, high employability of technologically advanced medical heart therapy devices and favourable compensation policies among other encouraging scenarios

Browse Full Report Description + Research Methodology + Table of Content + Infographics@

https://www.emergenresearch.com/industry-report/transcatheter-mitral-valve-implantation-market

For the purpose of this study, Emergen Research have segmented Transcatheter Mitral Valve Implantation Market on the basis of product, application, end use and region:

Product Outlook (Revenue in Million USD; 2019–2032)

  • Mechanical Valves
  • Bioprosthetic Tissue (Biological) Valves

Application Outlook (Revenue in Million USD; 2019–2032)

  • Mitral Valve Stenosis
  • Mitral Valve Prolapse
  • Mitral Valve Regurgitation

End Use Outlook (Revenue in Million USD; 2019–2032)

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Other

Regional Outlook (Revenue in Million USD; 2019–2032)

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Rest of the Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia-Pacific
    • Middle East & Africa
    • Latin America
      • Brazil

Curated Reports You Shouldn’t Miss: Dive In Now!

Blood Management and Diagnostics Market, By Technology, By Application (Oncology, Cardiovascular, Orthopedic, Gastrointestinal, Soft Tissue, Others), By End-Use (Hospitals, Ambulatory Surgical Centers) and By Region Forecast to 2032

Ventilator Filters Market, By Product Type (Bacterial/Viral Filters, Hygroscopic Condenser Humidifier (HCH) filters, and Others), By Application, By End-Use (Hospitals & Clinics, Home Care Settings, and Others), and By Region Forecast to 2032

Smart Beds and Surfaces Market, By Type (Manual, Semi-Automatic, and Automatic), By Application (Healthcare, Hospitality, and Residential), By Sales Channel, and By Region Forecast to 2032

Healthcare and Hospital Furniture Market, By Product (Beds, Patient Lift, Tables, Chairs, Medical Carts, Stretchers, and Others), By Material (, By Application, By Sales Channel, By End-use, and By Region Forecast to 2032

Synchronous Condenser Market, By Type (New Synchronous Condenser and Refurbished Synchronous Condenser), By Cooling Technology, By Starting Method, By Reacting Power Rating, By End-use, and By Region Forecast to 2032

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Explore Our Japanese Version: Transcatheter Mitral Valve Implantation Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Read our Press Release @ https://www.emergenresearch.com/press-release/global-transcatheter-mitral-valve-implantation-market

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.